2017 Press Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
11/09/17Histogenics Corporation Announces Third Quarter 2017 Financial and Operating Results
Top-line, 1-year Superiority Data for NeoCart® Phase 3 Clinical Trial and Potential Biologics License Application Filing Remain on Track for Third Quarter of 2018   Company to Host Conference Call and Webcast Thursday, November 9, 2017 at 8:30 a.m. ET  WALTHAM, Mass., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function, announced financia... 
Printer Friendly Version
10/26/17Histogenics Corporation to Report Third Quarter 2017 Financial Results on November 9, 2017
WALTHAM, Mass., Oct. 26, 2017 (GLOBE NEWSWIRE) -- Histogenics Corporation (Nasdaq:HSGX), a leading cell therapy company focused on developing and commercializing products in the musculoskeletal space, announced it will report its third quarter 2017 financial results on Thursday, November 9, 2017 before the U.S. financial markets open.  The Company will host a conference call and webcast at 8:30 a.m. ET to review financial and operational results for the quarter ended September 30, 2017 and pro... 
Printer Friendly Version
10/12/17Histogenics Corporation Promotes Stephen Kennedy to Executive Vice President & Chief Operating Officer
WALTHAM, Mass., Oct. 12, 2017 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a leading cell therapy company focused on developing and commercializing products in the musculoskeletal space, today announced the promotion of Stephen Kennedy from Chief Technology Officer to Executive Vice President & Chief Operating Officer, effective October 12, 2017.  Mr. Kennedy brings more than 30 years of executive product development, manufacturing, technology assessment and com... 
Printer Friendly Version
10/02/17Histogenics Announces Publication of Additional Biomechanical Data From Human Engineered Cartilage Testing
– Data Demonstrate the Importance of Generating Extracellular Matrix During Ex-Vivo Manufacturing of Cartilage Cell Therapy – – Ex-vivo Production of Extracellular Matrix is Critical to Biomechanical Competence and May Enable Earlier Return to Function After Treatment – – Presence of Extracellular Matrix at Time of Implantation Improves Biomechanical Competence of Cartilage Cell Therapy Compared to Therapies with Only Cells and Scaffold – WALTHAM, Mass., Oct. 02, 2017 (GLOBE NEWSWIRE) --... 
Printer Friendly Version
09/26/17Histogenics Corporation to Present at the 2017 Cell & Gene Meeting on the Mesa
WALTHAM, Mass., Sept. 26, 2017 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a leading cell therapy company focused on developing and commercializing products in the musculoskeletal space, today announced that Adam Gridley, President and Chief Executive Officer of Histogenics, will be participating in a panel discussion on tissue engineering on Wednesday, October 4, 2017 at 10:45 am PT and presenting a corporate overview during the meeting’s Partnering Forum on Wedne... 
Printer Friendly Version
08/24/17Histogenics Corporation to Present at Upcoming Investor Conferences
WALTHAM, Mass., Aug. 24, 2017 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced that Company Management will be presenting at three upcoming conferences in September 2017.  Baird 2017 Global Healthcare Conference – New York, NY (September 6-7, 2017) Jonathan Lieber, Chief Financial Officer of Histogenics, will be presenting a corporat... 
Printer Friendly Version
08/10/17Histogenics Corporation Announces Second Quarter 2017 Financial and Operating Results
‒ Completed Enrollment in NeoCart® Phase 3 Clinical Trial ‒ ‒ Top-line Data and Potential BLA Filing Expected in Third Quarter of 2018 ‒ ‒ Defined Regulatory Pathway with Japan Pharmaceuticals and Medical Devices Agency ‒ ‒ Market Research in U.S. and Japan Points to Potential Large Markets with Significant Unmet Need ‒ WALTHAM, Mass., Aug. 10, 2017 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commerciali... 
Printer Friendly Version
07/27/17Histogenics Corporation to Announce Second Quarter 2017 Financial Results on August 10, 2017
WALTHAM, Mass., July 27, 2017 (GLOBE NEWSWIRE) -- Histogenics Corporation (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, announced it will release its financial and operational results for the quarter ended June 30, 2017, on August 10, 2017 before the market opens.  Histogenics’ management will host a conference call on Thursday, August 10, 2017 at 8:30 a.m. EDT.  A question-and-answer session will follow Histo... 
Printer Friendly Version
07/26/17Histogenics Corporation to Present at the 37th Annual Canaccord Genuity Growth Conference
WALTHAM, Mass., July 26, 2017 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced that Adam Gridley, President and Chief Executive Officer of Histogenics, will present at the 37th Annual Growth Conference on Wednesday, August 9, 2017 at 10:00 AM EDT at the InterContinental Boston in Boston, MA.  This presentation will be webcast live and may b... 
Printer Friendly Version
07/11/17Histogenics Announces Publication of Data From Collagen and Chondrocyte 3-D Bioprinting Study
– Findings Augment Growing Body of Information to Support the Manufacture of Current and Next-Generation NeoCart® Implants –  – 3-D Bioprinting May Enable More Efficient Production of Next Generation NeoCart Implants – WALTHAM, Mass., July 11, 2017 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced the online publication in the Journal Biofabr... 
Printer Friendly Version
06/27/17Histogenics Completes Enrollment for Phase 3 Clinical Trial of Neocart® to Treat Knee Cartilage Damage
– On Track for Top-Line One Year Superiority Data and Potential BLA Filing in Third Quarter of 2018 – Articular cartilage can be damaged by injury or normal wear and tear (http://www.neocartimplant.com/cartilage-injury). – Novel Tissue Implant Potentially Ac... 
Printer Friendly Version
06/05/17Histogenics Corporation Announces the Appointment of Donald Haut, Ph.D. as Chief Business Officer
‒ Experienced Biotechnology Business Development & Strategic Planning Executive to Lead Commercial Partnership Activities ‒ WALTHAM, Mass., June 05, 2017 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, announced the appointment of Donald Haut, Ph.D. as its Chief Business Officer.  Dr. Haut brings more than 20 years of executive management experience in ... 
Printer Friendly Version
05/16/17Histogenics Corporation to Present at Upcoming Industry Conferences
WALTHAM, Mass., May 16, 2017 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced that Management will be presenting at several upcoming industry conferences.  12th World Advanced Therapies & Regenerative Medicine Congress – London, England (May 17-19, 2017) Adam Gridley, Histogenics’ CEO, will be participating in several panels disc... 
Printer Friendly Version
05/15/17Histogenics Corporation Receives Innovation Award
‒ Histogenics Recognized by the Smaller Business Association of New England (SBANE) as One of the Most Innovative Companies in the Region ‒ ‒ NeoCart® and Tissue Generation Platform Seen as a Potential Leading Solution to Treat Cartilage Defects ‒ WALTHAM, Mass., May 15, 2017 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, announced that it was one of the ... 
Printer Friendly Version
05/11/17Histogenics Corporation Announces First Quarter 2017 Financial and Operating Results
‒ NeoCart® Phase 3 Clinical Trial Enrollment Near Completion ‒ ‒ NeoCart Approval Pathway in Japan Defined After Successful Conclusion of Discussions with the Japan Pharmaceuticals and Medical Devices Agency ‒ ‒ Publication of Additional Data to Support Potential Approval and Commercialization of NeoCart ‒ ‒ Company to Host Conference Call and Webcast Today at 8:30 a.m. EDT ‒ WALTHAM, Mass., May 11, 2017 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerativ... 
Printer Friendly Version
05/08/17Histogenics Announces Agreement With the Japan Pharmaceuticals and Medical Devices Agency Regarding Japanese Regulatory Pathway for NeoCart®
– Long history and significant US data package may enable full Marketing and Manufacturing Authorization of NeoCart subject to successful completion of small confirmatory clinical trial in Japan – – PMDA Consultations concluded in first quarter of 2017 encompass all parts of potential regulatory submission including:  Clinical Trial, Quality/Manufacturing and Non-Clinical Safety – – Japanese cartilage repair market estimated to be second largest in the world with established reimbursement, a... 
Printer Friendly Version
04/27/17Histogenics Corporation To Announce First Quarter 2017 Financial Results on May 11, 2017
WALTHAM, Mass., April 27, 2017 (GLOBE NEWSWIRE) -- Histogenics Corporation (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, announced it will release its financial and operational results for the quarter ended March 31, 2017, on May 11, 2017 before the market opens.   Histogenics’ management will host a conference call on Thursday, May 11, 2017 at 8:30 a.m. EDT.  A question-and-answer session will follow Histogen... 
Printer Friendly Version
04/24/17Histogenics Corporation to Present at 5th Annual Cell & Gene Therapy Investor Day on April 27, 2017
WALTHAM, Mass., April 24, 2017 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced that Adam Gridley, President & CEO, will present at the Alliance for Regenerative Medicine’s 5th Annual Cell & Gene Therapy Investor Day on Thursday, April 27, 2017 at 2:15 pm ET in Boston. In addition, Mr. Gridley will participate in a panel titled "Cel... 
Printer Friendly Version
03/29/17Histogenics Corporation to Present at Needham & Company’s 16th Annual Healthcare Conference
WALTHAM, Mass., March 29, 2017 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced that Adam Gridley, Chief Executive Officer of Histogenics, will be presenting a corporate overview at Needham & Company’s 16th Annual Healthcare Conference on, April 5, 2017 at 09:20 AM EDT at the Westin Grand Central Hotel in New York, NY.  This presentatio... 
Printer Friendly Version
03/16/17Histogenics Corporation Announces Financial and Operating Results for the Fourth Quarter and Year Ended December 31, 2016
‒ NeoCart® Phase 3 Clinical Trial Enrollment on Track for Completion by End of Second Quarter of 2017 ‒ ‒ Strong Performance in all Areas of the Business in 2016 ‒ ‒ Financing Completed in the Third Quarter of 2016 Expected to Fund Company to Phase 3 Data ‒ ‒ Company to Host Conference Call and Webcast Today at 8:30 a.m. EDT ‒ WALTHAM, Mass., March 16, 2017 (GLOBE NEWSWIRE) --  Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and co... 
Printer Friendly Version
03/09/17Histogenics Announces Publication of Biomechanical and Structural Data From Human Engineered Cartilage Testing
– Data demonstrate Histogenics’ Tissue Engineered Cartilage Constructs Exhibit Mechanical Properties Approaching Native Human Cartilage as Early as Three Weeks in Culture and Prior to Implantation –  – First Study to Use Three Mechanical Tests to Examine and Understand the Performance of Repaired Cartilage in Accordance with FDA Guidance – WALTHAM, Mass., March 09, 2017 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on deve... 
Printer Friendly Version
03/02/17Histogenics Corporation to Announce 2016 Financial Results on March 16, 2017
WALTHAM, Mass., March 02, 2017 (GLOBE NEWSWIRE) -- Histogenics Corporation (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, announced it will release its financial and operational results for the quarter and year ended December 31, 2016, on March 16, 2017 before the market opens.  Histogenics’ management will host a conference call on Thursday, March 16, 2017 at 8:30 a.m. EDT. A question-and-answer session will f... 
Printer Friendly Version
02/23/17Histogenics Corporation to Present at Upcoming Investor Conferences
WALTHAM, Mass., Feb. 23, 2017 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced that Company Management will be presenting at two upcoming healthcare investor conferences.  Cowen and Company 37th Annual Health Care Conference – Boston, MA (March 6-8, 2017) Adam Gridley, Histogenics’ CEO, will be presenting a corporate overview on Mond... 
Printer Friendly Version
01/11/17Histogenics Announces Publication of MRI Data From NeoCart® Phase 1 and Phase 2 Clinical Trials in the American Journal of Sports Medicine
– Data demonstrate significant improvement in cartilage quality over first 24 months after treatment, with stabilization and maturation thereafter out to 60 months –  – Improvements in cartilage quality were accompanied by consistent and statistically significant improvements in patient reported clinical outcomes as early as 3 to 6 months after implantation –  – Data underscore potential to provide a faster and more durable recovery for patients with cartilage defects in the knee – WALTHAM, M... 
Printer Friendly Version